Send to

Choose Destination
See comment in PubMed Commons below
Ann Pharmacother. 1997 Jul-Aug;31(7-8):919-21.

Saccharomyces boulardii for the treatment of Clostridium difficile-associated colitis.

Author information

  • 1School of Pharmacy, West Virginia University, Morgantown 26506, USA.


S. boulardii has been investigated in Europe and the US, and preliminary reports indicate that it is safe and effective in conjunction with vancomycin or metronidazole for the treatment of CDC, predominantly in patients who develop recurrence. S. boulardii in combination with vancomycin or metronidazole has not been shown to be more effective than either of these agents alone for treatment of a first episode of CDC. In addition, S. boulardii has not been studied in immunocompromised patients who may be at risk for developing fungemia. Ultimately, large-scale clinical studies are necessary to determine whether S. boulardii should be routinely used to treat patients with recurrent CDC. S. boulardii is currently undergoing Phase III clinical trials for CDC treatment in the US. Clinicians interested in information regarding participation in current studies may contact Biocodex Inc., in Seattle, Washington.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center